Company research
Aptose Biosciences Inc.
CIK 882361Updated Sep 24, 2026
SecurityAPTOF · OTC · equity
Historical securities (1)
APS · TSX · equity · closed Jul 2, 2026Name history
Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) · through Nov 26, 2014LORUS THERAPEUTICS INC · through Sep 2, 2014IMUTEC PHARMA INC · through Mar 24, 1998
APTOF price & chart
Loading TradingView…
OTC:APTOF on TradingView ↗About the company
Aptose Biosciences Inc. (“Aptose,” the “Company,” “we,” “us,” or “our”) is a science-driven clinical stage biotechnology company committed to the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s executive offices are located in San Diego, California, and our head office is located in Toronto, Canada.
In the news
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical ↗
Recent filings
15-12G filing
SC 13E3/A filing
Completion of Acquisition or Disposition of Assets · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 2.01, 3.03, 5.01, 5.02, 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
SC 13E3/A filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 10,012,000Source | 10,127,000Source | 12,989,000Source | 51,027,000Source |
| Property, Plant and Equipment, NetUSD | 4,000Source | 26,000Source | 152,000Source | 211,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 935,000Source | 6,152,000Source | 9,252,000Source | 36,970,000Source |
| Assets, CurrentUSD | 6,446,000Source | 9,530,000Source | 11,894,000Source | 49,519,000Source |
| Operating Lease, Right-of-Use AssetUSD | 175,000Source | 571,000Source | 943,000Source | 1,297,000Source |
| Other Assets, NoncurrentUSD | 3,387,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 37,179,000Source | 14,670,000Source | 15,890,000Source | 13,286,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 459,771,000Source | 457,404,000Source | 444,806,000Source | 437,520,000Source |
| Additional Paid in CapitalUSD | 83,813,000Source | 83,336,000Source | 72,146,000Source | 68,869,000Source |
| Retained Earnings (Accumulated Deficit)USD | -566,435,000Source | -540,967,000Source | -515,537,000Source | -464,330,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,316,000Source | -4,316,000Source | -4,316,000Source | -4,318,000Source |
| Stockholders' Equity Attributable to ParentUSD | -27,167,000Source | -4,543,000Source | -2,901,000Source | 37,741,000Source |
| Liabilities and EquityUSD | 10,012,000Source | 10,127,000Source | 12,989,000Source | 51,027,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,306,000Source | 4,459,000Source | 15,269,000Source | 12,284,000Source |
| Operating Lease, Liability, CurrentUSD | 193,000Source | 428,000Source | 394,000Source | 301,000Source |
| Accounts Payable, CurrentUSD | 2,911,000Source | 1,258,000Source | 3,492,000Source | 6,326,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 193,000Source | 621,000Source | 1,002,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 6,202,000Source | 2,773,000Source | 8,829,000Source | 5,657,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 4,100,000Source | 6,700,000Source | 9,300,000Source | 47,000,000Source |
| Short-term InvestmentsUSD | — | — | — | 9,989,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 88,000Source | 120,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 477,000Source | 1,060,000Source | 3,653,000Source | 5,207,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | 4,627,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -21,990,000Source | -35,977,000Source | -44,590,000Source | -32,322,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | 18,000Source | 9,960,000Source | 30,066,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 5,000Source | 29,000Source | 24,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 19,379,000Source | 33,414,000Source | 6,910,000Source | 116,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -2,611,000Source | -2,545,000Source | -27,718,000Source | -2,144,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 477,000Source | 1,060,000Source | 3,653,000Source | 5,207,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 4,100,000Source | 6,700,000Source | 9,300,000Source | 47,000,000Source |
| DepreciationUSD | 22,000Source | 32,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | -4,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -7,000Source | -9,000Source | -2,000Source | -9,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | -76,000Source | 0Source | -16,000Source |
| General and Administrative ExpenseUSD | 13,382,000Source | 11,154,000Source | 15,591,000Source | 14,514,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | — | — |
| Investment Income, InterestUSD | 105,000Source | 357,000Source | 1,151,000Source | 788,000Source |
| Net Income (Loss) Attributable to ParentUSD | -25,468,000Source | -25,430,000Source | -51,207,000Source | -41,823,000Source |
| Nonoperating Income (Expense)USD | -745,000Source | 827,000Source | 1,149,000Source | 779,000Source |
| Operating ExpensesUSD | 24,723,000Source | 26,257,000Source | 52,356,000Source | 42,602,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 0Source | 15,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | 0Source | 0Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Income Tax Expense (Benefit)USD | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -25,468,000Source | -25,430,000Source | -51,207,000Source | -41,823,000Source |
| Earnings Per Share, BasicUSD per share | -10.41Source | -36.38Source | -7.58Source | -0.45Source |
| Earnings Per Share, DilutedUSD per share | -10.41Source | -36.38Source | -7.58Source | -0.45Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 2,447,353Source | 698,980Source | 6,755,000Source | 92,267Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 2,447,353Source | 698,980Source | 6,755,000Source | 92,267Source |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | -4,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -7,000Source | -9,000Source | -2,000Source | -9,000Source |
| General and Administrative ExpenseUSD | 13,382,000Source | 11,154,000Source | 15,591,000Source | 14,514,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -20,898,000Source | -21,564,000Source | -45,652,000Source | -36,615,000Source |
| Investment Income, InterestUSD | 105,000Source | 357,000Source | 1,151,000Source | 788,000Source |
| Nonoperating Income (Expense)USD | -745,000Source | 827,000Source | 1,149,000Source | 779,000Source |
| Operating ExpensesUSD | 24,723,000Source | 26,257,000Source | 52,356,000Source | 42,602,000Source |
| Research and Development ExpenseUSD | 11,341,000Source | 15,103,000Source | 33,273,000Source | 28,088,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | 0Source | 0Source | 0Source |
Offerings
Registration 333-284927
Filing attachments
d161768dex992.htm · 8-K · 2026-07-01
EX-99.2 2 d161768dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 For Immediate Release Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical SAN DIEGO and TORONTO, June 30, 2026 - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced the closing of the pl…
Read attachment ↗d70162dex991.htm · 8-K · 2026-02-24
EX-99.1 4 d70162dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Not For Immediate Release - Strictly Confidential - For Review Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders Aptose Biosciences and Hanmi Pharmaceutical to Further Extend Loan Agreement to Continue Development of Tuspetinib in Frontline Triplet Therapy for AML SAN DIEGO and TORONTO, February 23, 2026 - Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX…
Read attachment ↗d857719dex991.htm · 8-K · 2025-02-13
EX-99.1 4 d857719dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Not For Immediate Release - confidential for review Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility SAN DIEGO and TORONTO, February 13, 2025 - Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today…
Read attachment ↗